This inventor holds 0 USPTO granted patents, plus 3 CIPO patents.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Title: Michael Coleman: Innovator in Regenerative Cell Technology
Introduction
Michael Coleman is an inventive mind based in the United States, known for his contributions to the field of regenerative medicine. He has developed innovative solutions aimed at enhancing the growth and administration of regenerative cells. Although he currently holds no patents, his work has significant implications for treating joint diseases and other tissue-related ailments.
Latest Patents
Coleman's notable invention is titled "Media For Culturing, Preserving, And Administering Regenerative Cells." This innovative culture media, media supplement, or soluble matrix is designed for cryopreservation and enhanced regenerative cell growth. It includes a GAG composition, specifically a sulfated GAG such as chondroitin sulfate. The invention also encompasses a cell administration package or kit, which includes the soluble matrix and a device for cell administration. This method is intended for the administration of regenerative cells to treat joint diseases or other weakened or damaged tissues.
Career Highlights
Throughout his career, Michael Coleman has worked with several companies that focus on advancing medical technologies. Notably, he has been associated with Ingeneron Incorporated and Arthrodynamic Holdings, LLC. His experience in these organizations has allowed him to contribute to the development of innovative solutions in regenerative medicine.
Collaborations
Some of his notable coworkers include Ivone Bruno and Rudy Martinez. Their collaborative efforts have likely played a role in advancing the projects they have worked on together.
Conclusion
Michael Coleman is a dedicated inventor whose work in regenerative cell technology holds promise for future medical advancements. His innovative approaches to cell culture and administration are paving the way for new treatments in regenerative medicine.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile